Literature DB >> 32590095

Bio-synthesized iron oxide nanoparticles for cancer treatment.

Edouard Alphandéry1.   

Abstract

Various living organisms, such as bacteria, plants, and animals can synthesize iron oxide nanoparticles (IONP). The mechanism of nanoparticle (NP) formation is usually described as relying on the reduction of ferric/ferrous iron ions into crystallized nanoparticulate iron that is surrounded by an organic stabilizing layer. The properties of these NP are characterized by a composition made of different types of iron oxide whose most stable and purest one appears to be maghemite, by a size predominantly comprised between 5 and 380 nm, by a crystalline core, by a surface charge which depends on the nature of the material coating the iron oxide, and by certain other properties such as a sterility, stability, production in mass, absence of aggregation, that have apparently only been studied in details for IONP synthesized by magnetotactic bacteria, called magnetosomes. In the majority of studies, bio-synthesized IONP are described as being biocompatible and as not inducing cytotoxicity towards healthy cells. Anti-tumor activity of bio-synthesized IONP has mainly been demonstrated in vitro, where this type of NP displayed cytotoxicity towards certain tumor cells, e.g. through the anti-tumor activity of IONP coating or through IONP anti-oxidizing property. Concerning in vivo anti-tumor activity, it was essentially highlighted for magnetosomes administered in different types of glioblastoma tumors (U87-Luc and GL-261), which were exposed to a series of alternating magnetic field applications, resulting in mild hyperthermia treatments at typical temperatures of 41-45 °C, leading to the full disappearance of these tumors without any observable side effects.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alternating magnetic field; Anti-tumor activity; Cancer; GBM; Glioblastoma; Magnetic hyperthermia; Magnetosomes; Magnetotactic bacteria; Nano-oncology; Nanomedicine; Nanoparticle; Natural iron oxide nanoparticle

Year:  2020        PMID: 32590095     DOI: 10.1016/j.ijpharm.2020.119472

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Biosynthesis of magnetic iron oxide nanoparticles: a review.

Authors:  M J Jacinto; V C Silva; D M S Valladão; R S Souto
Journal:  Biotechnol Lett       Date:  2020-11-06       Impact factor: 2.461

Review 2.  Nanoparticle Effects on Stress Response Pathways and Nanoparticle-Protein Interactions.

Authors:  Shana J Cameron; Jessica Sheng; Farah Hosseinian; William G Willmore
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

3.  Enhancement of T2* Weighted MRI Imaging Sensitivity of U87MG Glioblastoma Cells Using γ-Ray Irradiated Low Molecular Weight Hyaluronic Acid-Conjugated Iron Nanoparticles.

Authors:  Haw-Ming Huang; Ping-Han Wu; Po-Chien Chou; Wen-Tien Hsiao; Hsin-Ta Wang; Hsin-Pei Chiang; Chi-Ming Lee; Shwu-Huey Wang; Yu-Cheng Hsiao
Journal:  Int J Nanomedicine       Date:  2021-06-01

4.  MSN, MWCNT and ZnO nanoparticle-induced CHO-K1 cell polarisation is linked to cytoskeleton ablation.

Authors:  Karmveer Yadav; Syed Azmal Ali; Ashok Kumar Mohanty; Eshwarmoorthy Muthusamy; Kesavan Subaharan; Gautam Kaul
Journal:  J Nanobiotechnology       Date:  2021-02-12       Impact factor: 10.435

5.  RGD Peptide-Conjugated Selenium Nanocomposite Inhibits Human Glioma Growth by Triggering Mitochondrial Dysfunction and ROS-Dependent MAPKs Activation.

Authors:  Wenjian Liu; Jing Su; Qiang Shi; Jinlei Wang; Xiao Chen; Shizhong Zhang; Mengkao Li; Jie Cui; Cundong Fan; Beibei Sun; Guojun Wang
Journal:  Front Bioeng Biotechnol       Date:  2021-12-23

Review 6.  Recent progress in advanced biomaterials for long-acting reversible contraception.

Authors:  Mingzhe Yan; Yanming Zhang; Zhihang Wu; Yifei Li; Keke Dou; Banghui Wang; Yingruo Wang; Qihui Zhou
Journal:  J Nanobiotechnology       Date:  2022-03-17       Impact factor: 10.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.